Literature DB >> 16939812

Retroviral integration site analysis identifies ICSBP as a collaborating tumor suppressor gene in NUP98-TOP1-induced leukemia.

Rhonna M Gurevich1, Patty M Rosten, Maike Schwieger, Carol Stocking, R Keith Humphries.   

Abstract

INTRODUCTION: The NUP98-TOP1 fusion gene is one of 18 distinct translocations identified in acute myeloid leukemia involving the N-terminal portion of the nucleoporin NUP98. We previously reported that expression of NUP98-TOP in murine bone marrow induces a lethal, transplantable leukemia. However, the long latency suggests the in vivo acquisition of additional mutations and/or time required for clonal outgrowth of rare transformed cells arising from the collaboration of NUP98-TOP1 and a cooperating event. The aim of this study was to test whether retroviral insertional mutagenesis contributes to disease onset and whether integration site analysis can identify collaborating genes.
METHODS: The genomic sites of retroviral integration in NUP98-TOP1-induced leukemic mice were analyzed. This screen identified a proviral integration that disrupts expression of the Interferon consensus sequence binding protein (ICSBP) tumor suppressor gene. Intriguingly, an ICSBP deficiency induces a chronic myeloid leukemia-like disease in mice and its reduced expression has been observed in several human leukemias. To ascertain whether an ISCBP deficiency collaborates with NUP98-TOP1 in leukemogenesis, we expressed NUP98-TOP1 in ICSBP(-/-) bone marrow.
RESULTS: The in vivo myeloproliferation induced by NUP98-TOP1 was markedly exaggerated with the ICSBP(-/-) deficiency. Moreover, NUP98-TOP1/ICSBP(-/-) mice had a reduced survival compared with NUP98-TOP1/ICSBP(+/+) mice.
CONCLUSION: These results reveal the novel finding of collaboration between the ICSBP tumor suppressor gene and NUP98-TOP1 in leukemogenesis. Moreover they further illustrate the power of retroviral integration site analysis for identifying novel cooperating tumor suppressor genes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939812     DOI: 10.1016/j.exphem.2006.04.020

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.

Authors:  A Sharma; H Yun; N Jyotsana; A Chaturvedi; A Schwarzer; E Yung; C K Lai; F Kuchenbauer; B Argiropoulos; K Görlich; A Ganser; R K Humphries; M Heuser
Journal:  Leukemia       Date:  2014-05-20       Impact factor: 11.528

Review 2.  NUP98 gene fusions and hematopoietic malignancies: common themes and new biologic insights.

Authors:  Sheryl M Gough; Christopher I Slape; Peter D Aplan
Journal:  Blood       Date:  2011-09-26       Impact factor: 22.113

3.  Identification of IRF8 as a potent tumor suppressor in murine acute promyelocytic leukemia.

Authors:  Coline Gaillard; Sangeetha Surianarayanan; Trevor Bentley; Matthew R Warr; Briana Fitch; Huimin Geng; Emmanuelle Passegué; Hugues de Thé; Scott C Kogan
Journal:  Blood Adv       Date:  2018-10-09

4.  IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia.

Authors:  Xiaolin Hu; Dafeng Yang; Mary Zimmerman; Feiyan Liu; Jine Yang; Swati Kannan; Andreas Burchert; Zdzislaw Szulc; Alicja Bielawska; Keiko Ozato; Kapil Bhalla; Kebin Liu
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

5.  Irf8 regulates the progression of myeloproliferative neoplasm-like syndrome via Mertk signaling in zebrafish.

Authors:  F Zhao; Y Shi; Y Huang; Y Zhan; L Zhou; Y Li; Y Wan; H Li; H Huang; H Ruan; L Luo; L Li
Journal:  Leukemia       Date:  2017-06-19       Impact factor: 11.528

Review 6.  Regulation of myelopoiesis by the transcription factor IRF8.

Authors:  Tomohiko Tamura; Daisuke Kurotaki; Shin-ichi Koizumi
Journal:  Int J Hematol       Date:  2015-03-07       Impact factor: 2.490

7.  The fusion partner specifies the oncogenic potential of NUP98 fusion proteins.

Authors:  Jesslyn Saw; David J Curtis; Damian J Hussey; Alexander Dobrovic; Peter D Aplan; Christopher I Slape
Journal:  Leuk Res       Date:  2013-09-21       Impact factor: 3.156

8.  Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukaemia line.

Authors:  Jane Rasaiyaah; Mahdad Noursadeghi; Paul Kellam; Benjamin Chain
Journal:  Immunology       Date:  2009-07       Impact factor: 7.397

9.  Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.

Authors:  Marina Scheller; Jörg Schönheit; Karin Zimmermann; Ulf Leser; Frank Rosenbauer; Achim Leutz
Journal:  J Exp Med       Date:  2013-10-07       Impact factor: 14.307

10.  Misregulation of Nucleoporins 98 and 96 leads to defects in protein synthesis that promote hallmarks of tumorigenesis.

Authors:  Ajai J Pulianmackal; Kiriaki Kanakousaki; Kerry Flegel; Olga G Grushko; Ella Gourley; Emily Rozich; Laura A Buttitta
Journal:  Dis Model Mech       Date:  2022-03-16       Impact factor: 5.758

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.